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Abstract
Background: The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower
growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage.
Objective: We performed a meta-analysis to accurately assess the effect of octreotide on pituitary tumor shrinkage.
Data Sources: A computerized Medline and Embase search was undertaken to identify potentially eligible studies.
Study Eligibility Criteria: Eligibility criteria included treatment with octreotide, availability of numerical metrics on tumor
shrinkage and clear definition of a clinically relevant reduction in tumor size. Primary endpoints included the proportion of
patients with tumor shrinkage and mean percentage reduction in tumor volume.
Data Extraction and Analysis: The electronic search identified 2202 articles. Of these, 41 studies fulfilling the eligibility
criteria were selected for data extraction and analysis. In total, 1685 patients were included, ranging from 6 to 189 patients
per trial. For the analysis of the effect of octreotide on pituitary tumor shrinkage a random effect model was used to account
for differences in both effect size and sampling error.
Results: Octreotide was shown to induce tumor shrinkage in 53.0% [95% CI: 45.0%–61.0%] of treated patients. In patients
treated with the LAR formulation of octreotide, this increased to 66.0%, [95% CI: 57.0%–74.0%). In the nine studies in which
tumor shrinkage was quantified, the overall weighted mean percentage reduction in tumor size was 37.4% [95% CI: 22.4%–
52.4%], rising to 50.6% [95% CI: 42.7%–58.4%] with octreotide LAR.
Limitations: Most trials examined were open-label and had no control group.
Conclusions: Octreotide LAR induces clinically relevant tumor shrinkage in more than half of patients with acromegaly.
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Introduction
Somatotropin release-inhibiting factor (somatostatin) acts by
signaling through specific receptor subtypes to suppress growth
hormone (GH) secretion by pituitary somatotroph tumor cells [1].
Long-acting somatostatin analogues act as somatostatin receptor
ligands and are widely used for the treatment of acromegaly either
as adjuvant or as primary therapy [2–4]. When treated with these
drugs approximately 50–75% of patients with acromegaly achieve
biochemical control, defined as GH ,2.5 mg/L and normal age-
and sex-adjusted insulin-like growth factor-I (IGF-I) levels [4,5].
There is growing evidence that somatostatin analogues also induce
tumor shrinkage in patients with acromegaly, although the
reduction in tumor size observed is not as dramatic and rapid as
that seen in patients with prolactinomas treated with dopamine
agonists [5–9]. The clinical significance of the effect of somato-
statin analogues on tumor shrinkage in patients with acromegaly
has been further enhanced by the widespread use of long-acting
somatostatin analogues as an alternative first-line therapy to
surgical tumor resection. In the first-line clinical setting, control of
both GH secretory activity and tumor growth are required in
order to achieve comprehensive therapeutic efficacy [10–15].
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ical control and tumor shrinkage may be dissociated and these
therapeutic endpoints require separate evaluation [16]. However,
in most published studies biochemical control of acromegaly has
been considered the main outcome of somatostatin analogue
therapy, while information regarding tumor shrinkage effects has
been limited due to a number of factors. These factors include the
differences in the number of patients studied, and heterogeneity in
study design in terms of patient inclusion criteria, length and type
of follow-up, imaging techniques and measurements used, type of
treatment (i.e. primary or adjuvant therapy) administered and the
use of different somatostatin analogues (i.e. lanreotide and
octreotide) [7,10–15,17–51].
Long-acting formulations of octreotide and lanreotide are the
only two somatostatin analogues currently approved for the
treatment of acromegaly. The two somatostatin analogues have
modest differences in their affinity for somatostatin receptor
subtypes as well as in their respective pharmacokinetic profiles
[52,53]. We recently performed a systematic review of the
literature on the effects of lanreotide on pituitary tumor shrinkage;
a meta-analysis was not possible due to the paucity of published
results for this drug, especially in its Autogel formulation [9]. In
contrast, there is an increasing body of literature concerning the
effects of octreotide on tumor shrinkage in patients with
acromegaly; octreotide was the first somatostatin analogue
introduced into clinical practice, and is still widely used for the
treatment of acromegaly [7,8]. Available analyses have been
performed several years ago and therefore on limited number of
patients particularly concerning the more modern drug formula-
tions [5,7,8]. We therefore performed a meta-analysis focused
specifically on both subcutaneous and intramuscular octreotide
formulations to objectively investigate the tumor shrinkage effects
of this drug in acromegaly. The determinants of the action of this
drug were also evaluated.
Methods
To avoid bias the methods for post hoc analysis and inclusion
criteria were specified in advance and protocol-defined.
Types of Studies and Endopoints
The searches were designed to select randomized and non-
randomized trials, conducted in patients with acromegaly who
were treated with octreotide, and which assessed a tumor
shrinkage effect. Sole eligibility criteria were the availability of
numerical metrics for tumor shrinkage, as well as a clear definition
of a clinically relevant reduction in tumor size. Studies with mixed
cohorts of patients treated with either octreotide or lanreotide were
excluded, unless results relating to each somatostatin analogue
type were reported separately.
The primary endpoint was tumor shrinkage evaluated as a
categorical (yes/no) variable. The secondary endpoint was the
relative reduction in tumor volume/mass from baseline evaluated
in studies where these data were reported [19,33,34,37,38,40,42–
44].
Search Strategies for Identification of Studies and Data
Extraction
A computerized Medline search up to November 2010 was
undertaken to identify potentially eligible studies; no language
limitation was applied [Table 1]. The same strategy was used to
search Embase. Reference lists from trials, narrative reviews, and
systematic reviews selected by electronic searching were hand
searched to identify additional eligible trials.
Identified studies were reviewed by title, abstract and keywords
to select potentially eligible studies. Thereafter, full articles were
studied to decide which studies met the inclusion criteria.
Eligibility assessment was performed independently by two
reviewers, a biostatistician and a clinician; if opinions differed,
they were resolved by mutual consensus.
Details of study design, patient characteristics, interventions,
and outcomes were independently extracted by two authors [G.M
and I.F.], using a data extraction form, pilot-tested on four
randomly-selected included studies and refined accordingly.
Differences in data extraction were solved by a third reviewer,
referring back to the original article.
Statistical Methods
For the primary endpoint, confidence intervals (CI) for estimates
of single study endpoints were obtained using exact methods; chi-
square distribution was used to test the association between
selected factors and response. Specifically planned evaluations
included: treatment (octreotide vs octreotide-LAR), proportion of
naive patients, duration of therapy (,1 year vs $1 year), type of
response (linear vs volume); type of lesion (micro- vs macroade-
noma); and biochemical response (‘‘safe’’ GH and normalized
IGF-I; treated as ordered variables and tested for trend effect).
Given the expected high heterogeneity among studies, a random
effect model was used to account for differences in both effect size
and sampling error; the between-studies variance was estimated
using the DerSimonian and Laird method; the overall effect was
estimated using the inverse variance method; the Q statistic was
used to assess study heterogeneity and the degree of heterogeneity
not explained by sampling error was quantified using the I
2 index;
Assessment of possible publication bias was performed by visual
inspection of the funnel plots and by formal analysis using the
Egger’s regression test. Statistical analysis was performed using the
SAS System, Release 9.2; forest plots were created using the SAS/
GRAPH Annotate Facility.
Results
Study Selection
The study selection process is depicted in Figure 1. Electronic
searches revealed 2202 articles, of which only 1547 were eligible
for the screening. 1422 articles did not meet the eligibility criteria
and were discarded. The full text of the remaining 125 studies was
fully examined. After examination of the full text, 84 studies were
excluded for the following reasons: 39 for reporting insufficient
data, 30 because of a different study aim, 7 because they were not
Table 1. Search strategy used to identify eligible published
clinical trials.
Database Query no. Search terms
PubMed 1 "Octreotide"[Mesh]
2 "Acromegaly"[Mesh]
3 #1 AND #2
4 #3 Limits: Humans, Publication Date to 2010–11–30
Embase 1 ‘octreotide’/exp
2 ‘acromegaly’/exp
3 #1 AND #2
4 #3 AND [humans]/lim NOT [30–11–2010]/sd
doi:10.1371/journal.pone.0036411.t001
Octreotide and Tumor Shrinkage in Acromegaly
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population, 1 because patients were duplicated in another
included study, and 1 because the report was preliminary.
Accordingly, 41 studies [10–15,17–51] fulfilling eligibility criteria
were selected for data extraction and analysis.
Study Characteristics
The characteristics of the 41 eligible studies are shown in
Table 2, and the characteristics of the eligible patients and the
study results are presented in Table 3. Two studies evaluated two
groups of patients with different doses of octreotide [25,50], and
therefore the results of 43 separate studies are presented. Sixteen-
hundred-eighty-five patients were included in the evaluable trials,
ranging from 6 to 189 patients per trial [Table 2]. Seven-hundred-
forty-eight patients were treated with intramuscular octreotide
LAR, while the remaining 937 patients received subcutaneous
octreotide [Table 2]. Nine hundred and forty-two patients (55.9%)
were treated with octreotide as first-line therapy [Table 2]. Data of
tumor shrinkage were available for 1172 patients (69.5%), ranging
from 6 to 90 per trial [Table 2, Figure 2].
Of the 41 studies, 32 measured tumor response according to
adenoma volume or size (cut-off varying from 10% to 30%),
whereas in the remaining 9 studies tumor shrinkage was defined
according to the decrease in the largest measurable adenoma
diameter [Table 2]. In over 50% of the studies, the pituitary tumor
was evaluated by magnetic resonance imaging whereas comput-
erized tomography was used in 18 studies (Table 2). The duration
of therapy ranged from 2 weeks to 30 months [Table 2]. Twelve
studies described a tumor shrinkage effect according to the type of
lesion (micro/macroadenoma), 37 provided information on the
percentage of patients with ‘‘safe’’ GH levels: i.e., random GH
levels below 2.0–2.5 mg/L in 23 studies [11–15,20,21,25,27,36–
42,44,46–51], random GH below 5 mg/L in 12 studies [17–
19,22,23,28,29,31–34,43] and suppressed GH values during oral
glucose tolerance test in two studies [30,35]. Thirty-one studies
reported the percentage of patients with normal IGF-I levels
[Table 3].
Tumor Shrinkage
Meta-analysis. Overall, in the 43 groups of patients evalu-
ated in the 41 studies, 53.0% (95%CI: 45.0%–61.0%) of patients
demonstrated a reduction in tumor size (Figure 2). Heterogeneity
in tumor reduction was very high (x
2 for heterogeneity: 433.850,
p,0.001; I
2=90.3), and was not explained by the use of a
different measurement of shrinkage (linear vs volumetric): I
2
reduced to 87.5 from 90.3 when stratifying by type of measure-
ment, and was still very high in both subgroups (linear: I
2=58.1;
volumetric: I
2=89.6). No evidence for a possible publication bias
was detected (p-value for the Egger’s test: 0.694). When the
analysis was restricted to studies in which stringent criteria for
tumor reduction were used (i.e., volume decrease of at least 20%)
[Table 2], 57.0% (95% CI: 47.0%–67.0%) of patients exhibited
tumor shrinkage. When the analysis was restricted to studies in
which tumor shrinkage was assessed by MRI, 60.0% (95% CI:
Figure 1. Search strategy and results.
doi:10.1371/journal.pone.0036411.g001
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Moreover, when the analysis was restricted to studies with follow-
up longer than 3 months, tumor shrinkage was seen to occur in
59.0% of patients (95% CI: 50.0%–68.0%) [Figure S2]. In an
analysis of the 9 studies in which the degree of shrinkage was
reported, the weighted mean percentage reduction in tumor size
was 37.4% (95% CI: 22.4%–52.4%), with the greatest effects
observed in patients treated with octreotide LAR compared with
subcutaneous octreotide (50.6% [95% CI: 42.7%–58.4%] vs
32.9% [95% CI 13.8%–52.0%], respectively; p=0.094) [Figure 3].
Analysis of determinants of tumor shrinkage. The effect
of treatment on tumor shrinkage was affected by several different
factors [Table 4]. Treatment resulted in significantly greater tumor
shrinkage if 1) tumor dimensions were reported as volume rather
than as a linear measurement (odds ratio [OR]: 2.73; 95% CI:
1.73–4.31; p,0.001); 2) patients had been treated with octreotide
LAR rather than subcutaneous octreotide (OR: 3.18; 95% CI:
1.95–5.20); p,0.001); 3) patients had a treatment duration longer
than 1 year as compared with a shorter treatment duration (OR:
1.90; 95% CI: 1.02–3.55; p=0.043); or 4) patients had received
octreotide as first-line therapy (OR increased according to the
higher proportion of treatment-naı ¨ve patients: p,0.001).
The correlation between tumor shrinkage and biochemical
response was also assessed; a positive relationship between tumor
shrinkage and the achievement of ‘‘safe’’ GH levels was observed:
in studies where higher rates (.75%) of ‘‘safe’’ GH levels were
observed, more patients experienced tumor shrinkage compared
with those studies in which ‘‘safe’’ GH control was less frequent
(,25%) (OR: 5.0; 95% CI 1.50–16.63; Table 4); a positive
correlation between tumor shrinkage and the attainment of
normal IGF-I level was also observed [Table 4]. Moreover, tumor
shrinkage did not correlate with the initial pre-treatment tumor
size [Table 4]. The unexplained variability, however, was always
.80% even after considering the effect of each of these variables.
Discussion
This meta-analysis shows that, overall, clinically significant
tumor shrinkage occurs in more than 50% of patients with
acromegaly treated with octreotide. Octreotide was the first
somatostatin analogue used for the treatment of acromegaly in
1984 and subsequently thousands of patients with acromegaly
have been treated with this agent [54,55]. The rationale for using
octreotide, like other somatostatin analogues, in the treatment of
acromegaly is based on the well known effect of somatostatin in
suppressing GH hypersecretion by pituitary tumor cells [1,56].
Besides biochemical effects, somatostatin and its analogues also
inhibit tumor cell growth [7,8]. This effect is of particular clinical
relevance because somatostatin analogues are increasingly being
used as first-line therapy in patients with acromegaly [10,59].
To date, several analyses have been published on the effects of
somatostatin analogues on tumor shrinkage in patients with
acromegaly [5,7–9]. Results of these critical analyses clearly
established that tumor shrinkage may occur in 40–50% of
acromegaly patients treated with somatostatin analogues, partic-
ularly when these drugs were used as first-line therapy [7,8].
Indeed, it has been suggested that somatostatin analogues may
control tumor growth in nearly all patients, since very few patients
experienced persistent tumor enlargement during medical therapy
[7]. However, at the time these analyses were published, available
data were sparse, particularly for octreotide LAR, which has only
been introduced into clinical practice in the past decade [60].
In recent years, a wealth of new clinical studies examining the
effects of somatostatin analogues including octreotide LAR in
patients with acromegaly has been published [9,13-15,41–51].
However, comparison of these studies in terms of their effects on
tumor shrinkage is challenging since they differ greatly in their
design. For example, there is marked heterogeneity in the length
and type of patient follow-up, the use of imaging techniques and
tumor measurements, the type of treatment administered (i.e.
primary or adjuvant therapy) and the type of drug employed
[9,13–15,41–51]. Consequently, we performed this meta-analysis
to objectively assess the magnitude of tumor shrinkage using all the
available data. We focused on octreotide, since data on lanreotide
Autogel (the other somatostatin analogue currently available in
clinical practice) are still too sparse to allow a rigorous meta-
analysis to be undertaken [9].
The studies identified by this meta-analysis have highly
heterogeneous study designs, and employed different criteria to
define tumor mass before and after therapy. Some studies
employed absolute or percentage changes in tumor diameter,
whereas others used absolute or percentage changes in tumor
volume. Our meta-analysis showed that the percentage of patients
experiencing tumor shrinkage was higher in studies reporting
changes in tumor volume than in those measuring changes in
tumor diameter. This observation is consistent with the assump-
tion that three-dimensional tumor measurements are more reliable
in detecting even small changes in tumor size [61].
Inherent limitations of all studies dealing with tumor shrinkage
are the arbitrarily chosen criteria used to define the clinical
significance of the treatment effect. This limitation is amplified
when a meta-analysis like this is performed, due to the reliance on
a single center definition of tumor shrinkage. Moreover, the
applied criteria were based exclusively on radiological evaluation;
clinical endpoints (e.g., improvement of visual fields) were not
consistently considered in single publications. Nevertheless, it is
now accepted that a 20% decrease in tumor size (volume or
diameter) may be considered a significant shrinkage. This metric is
reflective of the technical variability of assessment methods (which
are not believed to exceed this figure), the average baseline
adenoma dimensions (about 1.5–2.0 cm) in acromegaly and the
potential beneficial effects of relieving compression of surrounding
structures. Interestingly, several studies have reported longitudinal
data for the magnitude of tumor shrinkage [19,33,34,37,38,40,42–
44]. Therefore, our meta-analysis defined the phenomenon in
terms of prevalence and provided a quantitative evaluation.
Notably, while for short-acting subcutaneous octreotide, the
average shrinkage effect was just slightly higher than the threshold
of clinical significance, the mean reduction in tumor size in
patients treated with octreotide LAR was almost 50%. This
strongly suggests that the effects of octreotide LAR are more than
a simple radiological phenomenon and have significant implica-
tions for clinical practice.
Pituitary adenoma shrinkage is an important clinical effect of
somatostatin analogues particularly when used as first-line
treatment of acromegaly. Primary somatostatin analogue therapy
may be offered in selected patients with unacceptable anesthesio-
logical risk and in those harboring macroadenomas with little
likelihood of surgical cure [62]. In these situations the tumor
shrinkage effect of somatostatin analogues is desirable in addition
to biochemical disease control. This meta-analysis demonstrated
that octreotide, when used as first-line therapy, may produce
tumor shrinkage in about two-thirds of patients with acromegaly,
whereas this effect was seen less frequently when the drug was used
after surgical resection and/or radiotherapy. This finding may also
be explained, at least in part, by difficulties in evaluating tumor
shrinkage in patients who have previously undergone surgery or
radiotherapy. In fact, transsphenoidal resection induces anatom-
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PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e36411ical pituitary and sellar alterations that result in poor reproduc-
ibility when evaluating pituitary imaging [63]. Surgical packing
materials placed into the sella may re-absorb and the volume of
the residual mass may decrease, mimicking a shrinkage effect.
Previous radiotherapy may also alter the results of pituitary
imaging by causing fibrotic changes in the sellar content, which
prohibit precise tracing of tumor margins [63].
This meta-analysis also demonstrated that intramuscular
octreotide LAR produced tumor shrinkage in twice as many
patients as subcutaneous octreotide. A similar size effect was
observed with the quantitative analysis when the magnitude of
tumor shrinkage was evaluated. It is unlikely that such a difference
is attributable to technical reasons, such as differences in the
resolution of radiological tools employed in the older studies, in
which subcutaneous octreotide was evaluated, and the more recent
studies in which octreotide LAR was assessed [7]. It is more likely
that the advantage of octreotide LAR as compared to subcuta-
neous octreotide, observed in our meta-analysis, reflects a true
difference between the two formulations. Similar findings were
observed with lanreotide, when the Autogel formulation was
compared to the shorter term SR formulation [9]. This provides
convincing evidence that the biological effects of somatostatin
analogues may be influenced by their pharmacokinetic profiles;
prolonged and constant exposure of tumor cells to somatostatin
analogues may produce more evident anti-proliferative effects than
that achieved by short-term intermittent exposure.
The prediction of shrinkage effects of somatostatin analogues is
still controversial. Another factor thought to influence tumor
shrinkage is baseline tumor size. Although the literature on this
issue is controversial [11,12,24] our meta-analysis has revealed
that shrinkage of microadenomas and macroadenomas is compa-
rable with octreotide. Nevertheless, the clinical relevance of tumor
shrinkage may be greater in macroadenomas compared with
microadenomas, particularly considering the excellent results
obtained by experienced neurosurgeons with microadenomas
[62,64]. This meta-analysis demonstrated that the shrinkage effect
of octreotide correlated with duration of therapy, although the
literature indicates that shrinkage may occur in a number of
patients after short-term treatment with this drug [34,44]. This
finding may be important when octreotide therapy is proposed for
patients with macroadenomas and risk of compression of vital
structures.
Biochemical response has also been investigated as a determi-
nant of tumor shrinkage, but data on this question are also
controversial [7,8]. This meta-analysis showed that the prevalence
of tumor shrinkage was higher in patients achieving either ‘‘safe‘‘
GH levels, as defined by random values generally below 2.0–
2.5 ng/ml [57], or normalization of IGF-I. However, our analysis
showed that tumor shrinkage may occur even in patients who do
not achieve complete biochemical control under octreotide
treatment. Indeed, the possible dissociation between tumor
shrinkage and biochemical control has been described [9] and
may suggest different mechanisms underlying antimitotic and
antisecretory actions of somatostatin analogues [56,65]. In fact, it
has been demonstrated that the post-receptor pathways mediating
the antiproliferative effects of somatostatin analogues usually differ
from those involved in the antisecretory effects of these drugs [1].
Although somatostatin inhibits cell proliferation and may induce
tumor cell apoptosis, the mechanisms underlying the direct
antimitotic actions of octreotide have not been convincingly
demonstrated. Indirect effects of somatostatin analogues on
growth factor production and angiogenesis may also be involved
[7]. Results of this meta-analysis support the anti-tumor effects of
octreotide, a molecule that has also been extensively investigated
for treatment of neuroendocrine tumors in different organs [66].
In the future, clarification of the role of different somatostatin
receptor subtypes in mediating antimitotic effects [7], may provide
a helpful perspective on the effects of the multireceptor-targeted
somatostatin analogue pasireotide [67].
A major limitation of our meta-analysis, as for other similar
reports [5,68,69], was that most trials included in the analysis were
open-label and had no control group. Moreover, only few studies
aimed at assessing shrinkage as the main endpoint of the study and
no specific statistical hypothesis was formulated in many papers.
On the other hand, publication bias was not expected and indeed
was also excluded by a formal statistical test. Despite these
limitations, our results provide a comprehensive perspective on the
effect of first-line octreotide therapy on the shrinkage of GH-
secreting adenomas in patients with acromegaly. Indeed, clinically
significant tumor shrinkage was observed in more than 50% of
patients with acromegaly treated with octreotide.
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